Medicines: Atezolizumab

UK's National Health Service to roll out first cancer treatment jab | WION

WION

ESMO 2020 Expert Video report on atezolizumab in upfront treatment of TNBC

European Society for Medical Oncology (ESMO)

Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC

Atezolizumab and Bevacizumab Studied in Patients With Metastatic RCC

Targeted Oncology

The FDA Approval of Atezolizumab in Bladder Cancer

Title: Atezolizumab (MPDL3280A): Harnessing Immunotherapy's Promise in Cancer Treatment | GlpBio

Key outcomes of the Phase 1b of atezolizumab and bevacizumab for advanced HCC

Atezolizumab + Bevacizumab in Treatment-Naïve mRCC

Recent immunotherapy advances in HCC management

Tecentriq (atezolizumab) approved to treat Advanced Bladder Cancer

medXclusive Learning

Atezolizumab and bevacizumab for upfront unresectable HCC

Adjuvant atezolizumab in NSCLC

Cancer immunotherapy | The PD-L1 pathway

Dr. Horn Discusses Next Steps With Atezolizumab in SCLC

Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC

IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma

Immunotherapy Treatments for Non-Small Cell Lung Cancer (NSCLC)

You and Lung Cancer

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast Cancer

Dana-Farber Cancer Institute